Top Page
InhaleRx Limited
(Sydney:IRX)
InhaleRx Limited (IRX) vs. iShares MSCI Australia ETF (EWA)
InhaleRx Limited Business Overview & Revenue Model
InhaleRx Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 335.10K | 1.20M | 24.80K | 167.30K | 97.50K |
| Gross Profit | 335.10K | 1.20M | 15.09K | 52.07K | -26.43K |
| EBITDA | 0.00 | -1.41M | -1.94M | -1.12M | -1.22M |
| Net Income | -1.28M | -1.44M | -1.90M | -1.11M | -1.01M |
Balance Sheet | |||||
| Total Assets | 712.40K | 1.58M | 2.26M | 2.93M | 1.90M |
| Cash, Cash Equivalents and Short-Term Investments | 194.91K | 715.82K | 2.13M | 2.80M | 1.72M |
| Total Debt | 34.06K | 560.27K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 776.37K | 911.41K | 355.32K | 253.34K | 580.10K |
| Stockholders Equity | -63.97K | 665.47K | 1.90M | 2.68M | 1.32M |
Cash Flow | |||||
| Free Cash Flow | -368.77K | -1.96M | -1.85M | -1.19M | -1.09M |
| Operating Cash Flow | -368.77K | -1.96M | -1.85M | -1.16M | -1.09M |
| Investing Cash Flow | 0.00 | 0.00 | -175.00 | -25.09K | -4.30K |
| Financing Cash Flow | -152.14K | 544.29K | 1.18M | 2.26M | 2.37M |
InhaleRx Limited Technical Analysis
InhaleRx Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$313.78M | ― | -56.99% | ― | 10.76% | -195.89% | |
53 Neutral | AU$23.03M | ― | -218.38% | ― | -14.30% | 29.69% | |
52 Neutral | $4.60M | ― | -21.29% | ― | 80.87% | 82.44% | |
50 Neutral | AU$2.63B | 2.90 | -57.47% | 2.40% | 36.37% | 14.48% | |
46 Neutral | AU$9.77M | ― | -164.01% | ― | -18.80% | -46.65% | |
38 Underperform | AU$8.96M | ― | -191.40% | ― | ― | 19.74% |
InhaleRx Limited Corporate Events
InhaleRx Limited has announced that its Annual General Meeting will be held online on May 29, 2025, allowing shareholders to participate virtually. This move to an online-only format reflects the company’s adaptation to digital engagement, potentially increasing accessibility for stakeholders and aligning with contemporary corporate governance practices.
InhaleRx Limited has released a proxy voting form for its upcoming Annual General Meeting scheduled for May 29, 2025. The document outlines the procedures for shareholders to appoint proxies and direct their votes on various resolutions, including those related to the remuneration of key management personnel. This announcement is crucial for shareholders as it provides the necessary information to participate in the decision-making process, potentially impacting the company’s governance and strategic direction.
InhaleRx Limited has announced its upcoming Annual General Meeting (AGM), which will be held virtually on May 29, 2025. The meeting will address several key business items, including the consideration of the company’s financial statements for the year ended December 31, 2024, the adoption of the Remuneration Report, and the election and re-election of directors. Shareholders are encouraged to participate and vote on these matters as they hold significance for the company’s governance and strategic direction.
InhaleRx Limited’s recent quarterly cash flow report reveals a net cash outflow from operating activities amounting to $131,000, primarily due to expenditures on research and development, staff costs, and administration. Despite these outflows, the company maintained a stable cash position with no significant cash movements in investing or financing activities, indicating a focus on sustaining operations while managing expenses.
InhaleRx Limited has announced significant progress in its drug development efforts, supported by a $38.5 million funding agreement with Clendon Biotech Capital Pty Ltd. This funding will accelerate the development of IRX-211 and IRX-616a through to Phase 3 readiness, potentially expediting their path to market. The company has expanded the scope of its clinical trials and completed necessary adjustments for trial drug manufacturing, positioning itself to meet FDA requirements and enhance its market positioning.
InhaleRx Limited has completed its first drawdown of $247,500 from a $38.5 million funding facility with Clendon Biotech Capital, marking a significant step in its strategic partnership. This funding will support the commencement of clinical trials for IRX-211, a non-opioid treatment for Breakthrough Cancer Pain, and IRX-616a for Panic Disorder, aligning with the company’s goal to become a leader in inhaled therapies for pain and mental health. The partnership with Clendon is seen as crucial for delivering value to shareholders and advancing the company’s clinical development program.
InhaleRx Limited has announced the execution of a Study Order with iNGENū CRO Pty Ltd for a Phase 1 clinical trial of its drug candidate, IRX-616a, aimed at treating Panic Disorder. This milestone signifies a crucial advancement in the clinical development of IRX-616a, highlighting the company’s commitment to accelerating its clinical trial programs. The trial, which will be conducted in Adelaide, Australia, will assess the safety and efficacy of a cannabidiol inhaler in healthy volunteers. The company has secured funding to support its clinical development plans, positioning IRX-616a as a potential solution for the unmet need of rapid onset therapies for Panic Disorder.
InhaleRx Limited has reaffirmed its commitment to corporate governance by aligning with the ASX Corporate Governance Council Principles and Recommendations. The company has implemented a comprehensive governance framework, including a Board Charter and various policies such as Anti-Bribery, Risk Management, and Diversity. While the company has not yet set measurable objectives for gender diversity, it plans to do so as it grows, indicating a forward-looking approach to inclusivity.
InhaleRx Limited has released its corporate governance statement for the financial year ending December 31, 2024. The statement, approved by the board and current as of March 28, 2024, outlines the extent to which the company has adhered to the ASX Corporate Governance Council’s recommendations. The company has disclosed its board charter and other governance practices, ensuring transparency and accountability in its operations.
InhaleRx Limited reported a reduction in its annual loss by 16.2% for the year ending December 31, 2024, amounting to $1,209,373. Despite the improvement, the company did not declare any dividends, and its net tangible assets per ordinary security decreased significantly from 0.35 cents to -0.03 cents, indicating ongoing financial challenges.
InhaleRx Limited recently held a shareholder town hall webinar to discuss its progress in clinical development programs for its products IRX-211 and IRX-616a. The webinar, led by CEO Darryl Davies and Medical Advisor Dr. Sud Agarwal, highlighted the company’s advancements and future plans, generating significant interest from attendees. This engagement reflects positively on InhaleRx’s positioning in the industry as it continues to pursue innovative solutions for pain management and mental health, with potential economic benefits for shareholders.
InhaleRx Limited has announced the execution of a Study Order with iNGENū CRO Pty Ltd for a Phase 2 clinical trial of its non-opioid inhaled treatment, IRX-211, for Breakthrough Cancer Pain (BTcP). This trial, fully funded by Clendon Biotech Capital, aims to evaluate the efficacy, safety, and tolerability of IRX-211, addressing the urgent need for fast-acting pain relief alternatives to opioids. The study represents a significant milestone for InhaleRx in providing effective therapies for cancer patients and highlights the company’s commitment to addressing critical unmet medical needs in pain management.
InhaleRx Limited held a General Meeting where a sole resolution was voted on, and the company expressed gratitude to its shareholders for their support. The company announced an upcoming Town Hall webinar led by the CEO and Medical Advisor to update on recent developments and clinical progress, highlighting its commitment to advancing its position in the healthcare industry.
InhaleRx Limited has announced a shareholder town hall webinar scheduled for March 13, 2025, where the company’s CEO and Medical Advisor will provide updates on recent developments and progress in their clinical development program. This event highlights InhaleRx’s ongoing efforts to strengthen its position in the healthcare industry by addressing unmet medical needs and pursuing significant economic opportunities for its shareholders.
InhaleRx Limited announced the cessation of 250,000 securities due to the expiry of options or other convertible securities without exercise or conversion as of February 28, 2025. This development may impact the company’s capital structure and could influence investor perceptions, potentially affecting its market positioning and stakeholder interests.
InhaleRx Limited has announced the appointment of Tony Fitzgerald as a director, replacing James Barrie who has resigned but will remain as Company Secretary. Fitzgerald brings extensive experience in the life sciences and technology sectors, potentially enhancing the company’s strategic direction and industry positioning.